XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Related Information (Tables)
6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Revenue and Operating Income (Loss)
Segment revenue and operating income (loss) were as follows during the periods presented:
(in millions)DiagnosticsOtherTotal
Three months ended June 30, 2021
Revenues$177.1 $12.3 $189.4 
Depreciation and amortization15.7 1.2 16.9 
Segment operating income (loss)37.5 (58.3)(20.8)
Three months ended June 30, 2020
Revenues$81.0 $12.2 $93.2 
Depreciation and amortization16.7 1.0 17.7 
Segment operating loss(33.8)(34.5)(68.3)
Six months ended June 30, 2021
Revenues$334.9 $27.6 $362.5 
Depreciation and amortization32.7 2.6 35.3 
Segment operating income (loss)48.0 (115.5)(67.5)
Six months ended June 30, 2020
Revenues$231.5 $25.7 $257.2 
Depreciation and amortization33.5 2.1 35.6 
Segment operating loss(127.4)(74.6)(202.0)

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Total operating loss for reportable segments$(20.8)$(68.3)$(67.5)$(202.0)
Unallocated amounts:
Interest income0.2 0.5 0.4 1.3 
Interest expense(2.0)(3.1)(5.0)(5.4)
Other18.8 12.4 18.7 16.5 
Loss from operations before income taxes(3.8)(58.5)(53.4)(189.6)
Income tax expense (benefit)0.9 (3.0)(9.2)(18.9)
Net loss(4.7)(55.5)(44.2)(170.7)
Net loss attributable to non-controlling interest— (0.1)— (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)